Search results

ISSUE NO. 40 — Analytical Testing: Accurate and Complete Characterization of Your API to Maximize Bioavailability

Sep 23, 2024
- Manufacturing and Analytical Services
Event

The Golden Era of GLP-1 Drugs

Sep 9, 2024

Oct 3, 2024
- Clinical Trials
Blog

Case Study: How to Evaluate Human Abuse Potential (HAP) for CNS Drugs

Sep 6, 2024

Altasciences supported a client with HAP studies for the development of a novel analgesic, mirogabalin, currently marked in Japan, Korea, Taiwan, and China.
- Clinical Trials
Scientific Publication

Case Study—Nanosuspension Formulation to Maximize Potency for Preclinical Studies

Sep 6, 2024
- Manufacturing and Analytical Services
- Preclinical Research
Scientific Publication

Development of the Subject-Rated Comprehensive Drug Withdrawal Scale (CDWS) to Evaluate the Physical Dependence Potential of Investigational Drugs

Jun 20, 2024
- Clinical Trials
Scientific Publication

Pragmatic Considerations for the Application of Physical Withdrawal Assessments in Patient Studies

Jun 20, 2024
- Clinical Trials
Blog

Five Promising Treatment Areas in Early-Phase Drug Development in 2024

Apr 17, 2024

Explore emerging areas of drugs from psychedelics and gene therapy, oligonucleotides to GLP-1RA for metabolic disorders.